Expression and purification of virus-like particles for vaccination

Journal of Visualized Experiments

Volumn 2016, Issue 112, 2016, Pages

  Arevalo, Maria T ^a   Wong, Terianne M ^a   Ross, Ted M ^a  

^a UNIVERSITY OF GEORGIA   (United States)

Author keywords

Baculovirus; Insect expression; Issue 112; Mammalian expression; Medicine; Subviral particle; Vaccine design; Virus like particle

Indexed keywords

VIRUS VACCINE;

ANIMAL; CELL LINE; GENE VECTOR; VACCINATION;

ANIMALS; CELL LINE; GENETIC VECTORS; VACCINATION; VIRAL VACCINES;

EID: 84977597033     PISSN: 1940087X     EISSN: None     Source Type: Journal    
DOI: 10.3791/54041     Document Type: Article

References (19)

1. Zeltins, A. Construction and characterization of virus-like particles: a review. Mol Biotechnol. 53, 92-107 (2013).
2. Jain, N. K. et al. Formulation and stabilization of recombinant protein based virus-like particle vaccines. Adv Drug Deliv Rev. (2014).
3. Mair, C. M., Ludwig, K., Herrmann, A., & Sieben, C. Receptor binding and pH stability-how influenza A virus hemagglutinin affects hostspecific virus infection. Biochim. Biophys. Acta. 1838., 1153-1168 (2014).
4. Engerix-B [package insert]. GlaxoSmithKline, Research Triangle Park, NC (2013).
5. Giles, B. M. et al. A computationally optimized hemagglutinin virus-like particle vaccine elicits broadly reactive antibodies that protect nonhuman primates from H5N1 infection. J Infect Dis. 205, 1562-1570 (2012).
6. Giles, B. M., & Ross, T. M. A computationally optimized broadly reactive antigen (COBRA) based H5N1 VLP vaccine elicits broadly reactive antibodies in mice and ferrets. Vaccine. 29, 3043-3054 (2011).
7. Green, T. D. et al. C3d enhancement of neutralizing antibodies to measles hemagglutinin. Vaccine. 20, 242-248 (2001).
8. Bright, R. A. et al. Cross-Clade Protective Immune Responses to Influenza Viruses with H5N1 HA and NA Elicited by an Influenza Virus-Like Particle. PLoS ONE. 3, e1501 (2008).
9. Yondola, M. A. et al. Budding Capability of the Influenza Virus Neuraminidase Can Be Modulated by Tetherin. J Virol. 85, 2480-2491 (2011).
10. Schneider-Ohrum, K., & Ross, T. M. Virus-like particles for antigen delivery at mucosal surfaces. Curr Top Microbiol Immunol. 354, 53-73 (2012).
11. Murawski, M. R. et al. Newcastle disease virus-like particles containing respiratory syncytial virus G protein induced protection in BALB/c mice, with no evidence of immunopathology. J Virol. 84, 1110-1123 (2010).
12. Quan, F. S. et al. Viruslike particle vaccine induces protection against respiratory syncytial virus infection in mice. J Infect Dis. 204, 987-995 (2011).
13. Ross, T.M, Tang, X., Lu, H.R., Olagnier, D., Kirchenbaum, G.A., Evans, J.D. COBRA-Based Dengue Tetravalent Vaccine Elicits Neutralizing Antibodies Against All Four Dengue Serotypes. J Vaccine Immunotechnology. 1, 7 (2014).
14. World Health Organization. Manual for the Laboratory Diagnosis and Virological Surveillance of Influenza. World Health Organization (2011).
15. Mitnaul, L. J. et al. Balanced Hemagglutinin and Neuraminidase Activities Are Critical for Efficient Replication of Influenza A Virus. J Virol. 74, 6015-6020 (2000).
16. Jarvis, D. L. in Methods in Enzymology. Vol. Volume 463 eds R. Burgess Richard & P. Deutscher Murray 191-222 Academic Press (2009).
17. Pijlman, G. P. Enveloped virus-like particles as vaccines against pathogenic arboviruses. Biotechnol J. 10, 659-670 (2015).
18. Park, J. K. et al. Protective efficacy of crude virus-like particle vaccine against HPAI H5N1 in chickens and its application on DIVA strategy. Influenza Other Respir Viruses. 7, 340-348 (2013).
19. Gangadharan, D., Smith, J., & Weyant, R. Biosafety Recommendations for Work with Influenza Viruses Containing a Hemagglutinin from the A/goose/Guangdong/1/96 Lineage. MMWR. Recommendations and reports: Morbidity and mortality weekly report. Recommendations and reports / Centers for Disease Control. 62, 1-7 (2013).